Abstract
The associations of 18F-THK5351 tau positron emission tomography (PET) findings with core domains of progressive supranuclear palsy (PSP) and its diagnostic certainty have yet to be fully elucidated. The 18F-THK5351 PET patterns of 17 patients with PSP (68.9 ± 6.5 years; 8 women) were compared with those observed in 28 age-matched and sex-matched (66.2 ± 4.5 years, 18 women) control subjects (CS). Tracer accumulation—as reflected by standardized uptake value ratios (SUVRs) and z-scores—was correlated with core domains of PSP and different levels of diagnostic certainty. Compared with CS, patients with PSP showed an increased 18F-THK5351 uptake in the globus pallidus and red nucleus. Patients with PSP and oculomotor dysfunction had significantly higher SUVRs in the midbrain, red nucleus, and raphe nucleus than those without. In addition, cases who meet criteria for level 1 (highest) certainty in the postural instability domain showed significantly higher SUVRs in the frontal, parietal, precuneus, and sensory-motor cortex. Patients with probable PSP had significantly higher SUVR values than those with possible PSP in multiple cortical (i.e., frontal, parietal, temporal, anterior cingulate gyrus, precuneus, and sensory-motor gyrus) and subcortical (i.e., putamen, thalamus, and raphe nucleus) regions. Patterns of 18F-THK5351 uptake were correlated to core domains of PSP—including oculomotor dysfunction and postural instability. Moreover, the degree of diagnostic certainty for PSP was appreciably associated with 18F-THK5351 PET findings.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Introduction
Progressive supranuclear palsy (PSP) is a severe progressive atypical parkinsonian syndrome characterized by supranuclear gaze palsy, axial rigidity, postural instability, and cognitive dysfunction1. The neuropathological hallmark of the disease consists in the intra-neuronal aggregation of four-repeat tau fibrils in the subthalamic nucleus, globus pallidus, substantia nigra, red nucleus, oculomotor nucleus, and cortical regions2,3,4.
PSP remains diagnostically challenging as patients with typical signs and symptoms can have different underlying pathologies; conversely, cases who share identical neuropathological findings may differ in terms of clinical presentations5,6. Ultimately, the definite diagnosis of PSP requires post-mortem neuropathological examination. In a recent milestone, the International Parkinson and Movement Disorder Society (MDS) has outlined clinical diagnostic criteria for PSP and its four core domains (oculomotor dysfunction, postural instability, akinesia, and cognitive dysfunction). In doing so, different degrees of diagnostic certainty were proposed—resulting in sensitivity and specificity values > 85% in a neuropathologically-defined cohort7,8. The application of the new MDS criteria is expected to facilitate the clinical diagnosis of classic (PSP–Richardson syndrome) and variant presentations of PSP in a more accurate fashion7,9. Notably, four different clinical subtypes of PSP can be distinguished based on the presence of various core domains10.
Neuroimaging findings may be useful to support the clinical diagnosis of PSP. The anteroposterior diameter of midbrain and the midbrain-to-pons ratio measured on magnetic resonance (MR) imaging are recognized imaging biomarkers of classic PSP11. Positron emission tomography (PET) can also play a role in excluding or confirming the diagnosis of PSP when 18F-fluorodeoxyglucose (FDG) or dopamine-based tracers are used12,13,14. Moreover, tau PET ligands (e.g., 18F-AV-1451 and 18F-THK5351)—which can trace tau fibrils in the brain—have been investigated in patients with PSP15. An enhanced 18F-AV-1451 uptake has been reported in the putamen and globus pallidus of patients with PSP and has been shown to correlate with the PSP rating scale16,17. However, other studies failed to demonstrate an association between 18F-AV-1451 accumulation and measures of motor dysfunction or longitudinal changes in the PSP rating scale 18,19. An autopsy study also reported that tau neuropathology in the basal ganglia correlated with FDG—but not 18F-AV-1451—uptake20. The early development of tau-tracer is suffering from the off-target binding to monoamine oxidase B (MAO-B)21,22. Nonetheless, astrogliosis-related MAO-B elevation is a common histopathological known feature of all parkinsonian syndromes, and there is consistent evidence that accumulation of 18F-THK5351 in PET images obtained from living patients correlates with symptom severity and post-mortem tau pathology in PSP brains23,24,25.
The associations of 18F-THK5351 PET findings with core domains of PSP and its diagnostic certainty have yet to be fully elucidated. We set out to examine this issue in the current study of patients with PSP (diagnosed according to the new MDS criteria) and age- and sex-matched control subjects (CS).
Materials and methods
Study population
We examined 17 patients with PSP (68.9 ± 6.5 years; 8 women) and 28 age-matched and sex-matched CS (66.2 ± 4.5 years, 18 women). All cases were recruited from tertiary medical centers and had PSP diagnosed according to the MSD criteria. Patients were excluded if they were taking monoamine oxidase inhibitors (MAOI). Demographic characteristics, age at disease onset, and time from diagnosis to PET imaging were obtained from all participants. The degrees of diagnostic certainty for PSP in general (i.e., definite PSP, probable PSP, possible PSP, and suggestive of PSP) and for each of the four core domains were assigned according to the MDS criteria. Control subjects had a Mini-Mental State Examination score above the optimal cut-off according to their age and education26. Participants were excluded if they had a history of stroke, head trauma, or alcoholism. All procedures complied with the tenets of the 1964 Helsinki Declaration and its later amendments. All participants gave written informed consent and the study protocol was approved by the Institutional Review Board of the Chang Gung Memorial Hospital (CGMHIRB No. 201601674A0). The study was registed in clinicaltrials.gov (NCT03386669) on December 21, 2017.
Image acquisition
18F-THK5351—which was synthesized and prepared at the cyclotron facility of the Chang Gung Memorial Hospital27—was administed intravenously (378 ± 17 MBq) and patients rested confortably for 60 min. PET/CT was performed on a Siemens Biograph mCT 16 scanner (Siemens, Erlangen, Germany) and images were reconstructed using the three-dimensional ordered subset-expectation maximization algorithm (24 subsets and 4 iterations; Gaussian filter = 2 mm; zoom = 3). A CT scan was performed for attenuation correction, along with scatter and random corrections. Reconstructed images had a matrix size of 400 × 400 × 148 (voxel size, 0.68 × 0.68 × 1.5 mm3)28. Brain MR was performed on a 3-T scanner (Magneton Trio, Siemens) with the following sequences: (1) axial fluid attenuation inversion recovery (FLAIR) (TR = 9000 ms, TE = 87 ms, T1 = 2500 ms, voxel size = 0.9 × 0.7 × 4 mm3); (2) axial three-dimensional (3D) high resolution T1-weighted magnetization prepared rapid acquisition gradient echo (MP-RAGE) (TR = 2000 ms, TE = 2.63 ms, T1-900 ms, flip angle = 9°, voxel size = 1 × 1 × 1 mm3); and (3) coronal T2-weighted turbo spin echo (TR = 7,400 ms, TE = 95 ms, voxel size = 0.4 × 0.4 × 2 mm3) perpendicularly to the long hippocampal axis.
Image analysis
All imaging data were transformed for further processing into the Neuroimaging Informatics Technology Initiative (NIFTI) format using the PMOD image analysis software (version 3.7; PMOD Technologies Ltd., Zurich, Switzerland). Standardized uptake value images from 18F-THK5351 PET and T1-weighted MR images in the native space were analyzed in parallel for each participant. Anatomical coregistration was performed by analyzing PET and MR images simultaneously using the SPM12 toolbox (https://www.fil.ion.ucl.ac.uk/spm/software/spm12) as previously described29,30. 18F-THK5351 PET and MR images were carefully matched using anatomical landmarks, and the Muller-Gartner method was used for partial volume correction31. Native high-resolution MR images were normalized to the Montreal Neurological Institute (MNI) standard space using the normalization toolbox provided in SPM1232. The transform matrix was subsequently applied to PET images. The mean intensity across the cerebellar gray matter was used as the reference region for calculation of standardized uptake value ratios (SUVRs) from 18F-THK5351 PET images24. Fifteen regions of interest (ROIs) were selected according to the published literature and the Harvard–Oxford cortical structural atlas18,24,33. Bilateral cortical (i.e., frontal, parietal, temporal, occipital lobes, sensory-motor cortex, anterior cingulate gyrus, and precuneus) and subcortical (i.e., caudate, putamen, globus pallidus, thalamus, red nucleus, midbrain, raphe nucleus, and dentate nucleus) regions were included. SUVRs were assessed for each ROI. Means and standard deviations for SUVRs were determined from PET images of CS. For each participant, z-transformed images were calculated according to the following formula: (individual SUVR image—mean SUVR image)/standard deviation of SUVR image. Mean z-values for each ROI were derived from z-transformed 18F-THK5351 PET SUVR images. MR images were analyzed in the native space on the mid-sagittal view. Upon measurements of midbrain and pons diameters, the midbrain-to-pons ratio (midbrain diameter/pons diameter) was calculated as described previously34.
Statistical analysis
Summary statistics for continuous variables were presented as mean ± standard deviation and 95% confidence intervals, and comparisons between groups were performed using ANOVA with Bonferroni multiple comparison. Categorical data were summarized as frequencies and percentages, and differences between groups were analyzed with the chi-squared test. Adjustment for age and sex with linear regression was applied when regional SUVR values were compared. When core domains were analyzed, postural instability (n = 16) and akinesia (n = 17) were common, whereas oculomotor (n = 8) and cognitive (n = 2) dysfunction occurred more rarely. Owing to their high frequency, a subgroup analysis of the two first domains was performed based on the degree of diagnostic certainty, as follows: postural instability, P1 group (n = 8) versus non-P1 group (n = 8); akinesia, A1 group (n = 9) versus non-A1 group (n = 6). When a core domain occurred rarely (i.e., oculomotor and cognitive dysfunction), the degree of certainty was considered higher8 and subgroup analyses were not implemented8. Linear regression was used to analyze associations between MR parameters and 18F-THK5351 PET imaging variables in patients with PSP. All analyses were untaken using SPSS, version 21.0 (IBM, Armonk, NY, USA). Two-tailed p values < 0.05 were considered statistically significant.
Results
Sample characteristics
The general characteristics of the study participants are presented in Table 1. Patients with PSP were of similar age (p = 0.17) and sex (p = 0.26) as CS. The mean time interval from disease onset to imaging for patients with PSP was 6.6 ± 3.8 years. There were no significant correlations between disease duration and midbrain-to-pons ratios on MR or SUVRs from 18F-THK5351 PET. The results for core domains of PSP and diagnostic certainty are shown in Table 2. Postural instability and akinesia (as noted above) were commonly observed, whereas oculomotor and cognitive dysfunction were rare. The following degrees of diagnostic certainty for PSP were identified: probable PSP (n = 7), possible PSP (n = 5), and suggestive of PSP (n = 5).
Regional mean SUVRs differences
Representative 18F-THK5351 PET images obtained from a patients with PSP and a CS are shown in Fig. 1. We found no intergroup differences in regional mean SUVRs values measured in the frontal, parietal, temporal, and occipital cortex, as well as in the precuneus and anterior cingulate gyrus (Table 3). As for subcortical regions, patients with PSP showed an increased 18F-THK5351 accumulation in the globus pallidus and red nucleus compared with CS (all p < 0.05). More details regarding to left and right hemisphere measurements are shown in Supplementary Table 1. Similar results were observed for z-transformed 18F-THK5351 PET SUVR images (Fig. 2). 18F-THK5351 uptake was significantly lower in the caudate and thalamus of patients with PSP compared with CS (all p < 0.05). The impact of age and sex on 18F-THK5351 accumulation was investigated in the entire study sample. Men had significantly higher mean SUVR values (3.79 ± 0.89) in the red nucleus than women (3.29 ± 0.69, p = 0.01). Age was positively associated with 18F-THK5351 SUVR values in the putamen (p = 0.0003), globus pallidus (p = 0.001), and dentate nucleus (p = 0.02). Adjustment for age and sex revealed no statistically significant association between an increased 18F-THK5351 accumulation in the red nucleus in patients with PSP compared with CS (p = 0.06; Fig. 3). Conversely, there was a lower tracer uptake in the caudate (p = 0.0008) and thalamus (p = 0.001) of patients with PSP. The low uptake possibly due to radioactivity underestimate by spill-in from ventricle in PSP subjects with severe brain atrophy even after partial volume correction.
18F-THK5351 PET findings, core domains of PSP, and diagnostic certainty
Patients with ocolomotor dysfunction had significantly higher SUVR values (3.37 ± 0.47) in the midbrain region compared with those without (2.47 ± 0.72, p = 0.008, Fig. 4). Similar higher values were observed in the red nucleus (present versus absent: 4.61 ± 0.75 versus 3.23 ± 0.91, respectively, p = 0.02) and in the raphe nucleus (present versus absent: 6.45 ± 0.86 versus 3.93 ± 1.71, respectively, p = 0.002; Fig. 4). Patients who meet level 1 certainty criteria for the postural instability domain showed significantly higher SUVRs in the frontal (p = 0.04), parietal (p = 0.03), precuneus (p = 0.02) and sensory-motor cortex (p = 0.003; Fig. 4). However, no significant differences were observed for subcortical regions. 18F-THK5351 uptake in cortical and subcortical regions did not differ significantly with respect to the akinesia and cognitive dysfunction domains. As for diagnostic certainty, SUVR values were significantly higher in patients with probable PSP than in those with possible PSP in multiple cortical regions—including frontal (p = 0.03), parietal (p = 0.009), and temporal (p = 0.01) cortex, as well as in the anterior cingulate gyrus (p = 0.009), precuneus (p = 0.03) and sensorimotor gyrus (p = 0.02). Similar findings were observed for the following subcortical regions: putamen (p = 0.02), thalamus (p = 0.01), and raphe nucleus (p = 0.02).
Relations between MR findings, PSP core domains, and levels of diagnostic certainty
The MRI analysis between patients with PSP and CS showed a significantly smaller midbrain diameter (PSP vs CS = 9.59 ± 0.19 vs 10.86 ± 0.15, p < 0.01) and a smaller midbrain-to-pons ratio (PSP vs CS = 0.57 ± 0.01 vs 0.63 ± 0.01, p < 0.01). The is no significant between group difference in pons diameters (p = 0.13). There was no significant difference in the midbrain-to-pons ratio for patients with and without ocolomotor dysfunction (p = 0.08). This variable was unrelated to postural instability (P1 versus non-P1, p = 0.83), akinesia (A1 versus non-A1, p = 0.56), and cognitive dysfunction (present versus absent, p = 0.13). Neither diagnostic certainty nor different clinical phenotypes of PSP showed significant associations with midbrain diameters or midbrain-to-pons ratios.
Relations between midbrain-to-pons ratio and regional SUVR values
The MRI midbrain diameter showed a negative correlation with SUVR values in the red nucleus and globus pallidus (Fig. 5A). Similarly, the MRI midbrain-to-pons ratio was inversely related to SUVR values in the red nucleus and raphe (Fig. 5B). These associations persisted even after adjustment for age and sex in red nucleus (p = 0.030 and p = 0.033, respectively).
Discussion
There are six main findings from our study, as follows: (1) SUVR values in the globus pallidus and red nucleus from 18F-THK5351 PET imaging can differentiate between patients with PSP and CS; (2) patients with PSP and oculomotor dysfunction have significantly higher SUVR values in the midbrain, red nucleus, and raphe nucleus than those without; (3) patients with PSP who meet level 1 certainty criteria for the postural instability domain show significantly higher SUVRs in the frontal, parietal, precuneus, and sensory-motor gyrus; (4) SUVR values in multiple cortical and subcorticol regions are significantly higher in patients with probable PSP than in those with possible PSP; (5) regional SUVRs values measured in the red nucleus and midbrain regions are inversely related to the midbrain-to-pons ratio measured on MRI; (6) neither diagnostic certainty nor clinical phenotypes of PSP are significantly associated with the midbrain-to-pons ratio.
Diagnostic criteria and tau PET imaging in patients with PSP
Several PET studies have used first-generation tau ligands (e.g., 18F-AV1451) to examine the patterns of tracer uptake in relation to the clinical features of PSP diagnosed according to the new MSD criteria17,35. In general, patients with PSP are characterized by an increased 18F-AV1451 accumulation in the midbrain, basal ganglia, and dentate nuclear regions; however, similar patterns do not seem disease-specific as they have been observed in CS of similar age16. Moreover, subcortical tracer accumulation in PSP is not related to clinical symptoms18. Of note, pathological studies have shown that 18F-AV1451 binds with relatively low affinity to tau deposits—frequently in the same range of CS36,37. Differently from 18F-AV1451, 18F-THK5351 is characterized by a higher binding selectivity to tau deposition occurring in PSP brains23,25. Moreover, 18F-THK5351 PET findings have been shown to correlate with clinical symptoms and severity in patients with PSP diagnosed according to the National Institute of Neurological Disorders and Stroke and the Society for PSP (NINDS-SPSP) criteria9,24.
To our knowledge, this study is the first to describe 18F-THK5351 PET findings in patients with PSP who were diagnosed according to the new MDS criteria. Interestingly, both SUVR values and z-scores in the globus pallidus and red nucleus were able to distinguish patients with PSP from CS. It is therefore possible that tau accumulation in these areas as assessed by 18F-THK5351 PET imaging may have diagnostic utility in PSP. However, interpretation of PET results obtained with first-generation tau tracers can be made difficult by off-target tracer binding to neuromelanin and/or hemorrhagic lesions, as well as by the use of MAOI23,38. Although 18F-THK5351 PET and MR images were carefully matched, our results should be interpreted cautiously and require confirmation in future independent studies using second-generation tau ligands—including MK-6240, 18F-JNJ64349311, and 18F-APN160739,40.
18F-THK5351 PET findings and PSP core domains
The new MDS criteria for PSP diagnosis set out four core disease domains and four distinct levels of diagnostic certainty. The combination of different core domains allows identifying distinct PSP subtypes. As for diagnostic certainty, low scores reflect a greater diagnostic confidence8. A previous MR study investigated the imaging correlates of oculomotor dysfunction and postural instability41. The results revealed that alterations in the midbrain region and the superior cerebellar peduncle were associated with vertical oculomotor dysfunction and postural instability, respectively. The relation between midbrain damage and oculomotor dysfunction has been subsequently confirmed in independent studies42,43. Our 18F-THK5351 PET findings indicate that oculomotor dysfunction is associated with higher SUVR values in the midbrain, red nucleus, and raphe nucleus—a result in accordance with published MR studies. A further confirmatory observation is the inverse correlation between the midbrain-to-pons ratio and SUVR values in the raphe nuclear and red nuclear within the midbrain region. Nonetheless, the midbrain-to-pons ratio per se showed no association with the presence of oculomotor dysfunction. However, we found that patients with PSP who met level 1 certainty criteria for the postural instability domain showed significantly higher SUVRs in the frontal, parietal, precuneus, and sensory-motor gyrus—suggesting an increased tau accumulation in these areas. A previous MR investigation demonstrated that atrophy of the superior cerebellar peduncle may be an imaging feature of early postural instability in PSP−Richardson’s syndrome41. Other studies have identified microstructural damage to the corpus callosum and thalamic dysfunction as potential substrates for postural instability in patients with PSP44,45. To our knowledge, there are no previous investigations of tau imaging in relation to PSP-associated postural instability. However, post-mortem findings from a patient with PSP and predominant postural instability revealed an increased tau accumulation in the frontal and parietal lobes46—a finding in accordance with our current data. Herein we show that 18F-THK5351 PET imaging may increase the diagnostic sensitivity for postural instability in PSP from 37 to 51%, ultimately indicating the clinical utility of this imaging modality.
18F-THK5351 PET findings and PSP diagnostic certainty
The present study is the first to correlate 18F-THK5351 PET findings with different levels of diagnostic certainty for PSP. Our data indicate that patients with probable PSP had significantly higher SUVR values than those with possible PSP in multiple cortical (i.e., frontal, parietal, temporal, anterior cingulate gyrus, precuneus, and sensory-motor gyrus) and subcortical (putamen, thalamus, and raphe nucleus) regions—a result consistent with published neuropathology findings4. These data suggest that a higher burden of tau accumulation corresponds to a greater degree of diagnostic certainty. Albeit preliminary, our results may prompt additional investigations into the role of 18F-THK5351 PET as an imaging tool to increase the diagnostic certainty of PSP.
Limitations
This study has several potential weaknesses. We recognize that neuropathological assessment of the post-mortem brain is required to reach a definitive diagnosis of PSP. In the small sample examined, most patients had PSP–Richardson’s syndrome and no general conclusions can be drawn for other PSP subtypes. Moreover, 18F-THK5351 is an early-generation tau ligand that may exhibit off-target binding15. In this context, it is possible that areas of increased tracer uptake might not simply reflect tau deposition, but the presence of astrogliosis (either with or without other neuropathological alterations)47. Finally, image coregistration and correction for partial volume effects were based on a complex approach. However, we cannot rule out the presence of residual confounding deriving from the presence of atrophy in specific areas (e.g., caudate and thalamus). Other spatial transformation tools may help refine our approach in future studies48.
Conclusion
Patterns of 18F-THK5351 uptake were correlated to core domains of PSP—including oculomotor dysfunction and postural instability. Moreover, the degree of diagnostic certainty for PSP was appreciably associated with 18F-THK5351 PET findings.
Change history
09 February 2021
A Correction to this paper has been published: https://doi.org/10.1038/s41598-021-83535-z
References
Steele, J. C., Richardson, J. C. & Olszewski, J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch. Neurol. 10, 333–359. https://doi.org/10.1001/archneur.1964.00460160003001 (1964).
Dickson, D. W., Ahmed, Z., Algom, A. A., Tsuboi, Y. & Josephs, K. A. Neuropathology of variants of progressive supranuclear palsy. Curr. Opin. Neurol. 23, 394–400. https://doi.org/10.1097/WCO.0b013e32833be924 (2010).
Kovacs, G. G. Invited review: Neuropathology of tauopathies: Principles and practice. Neuropathol. Appl. Neurobiol. 41, 3–23. https://doi.org/10.1111/nan.12208 (2015).
Litvan, I. et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J. Neuropathol. Exp. Neurol. 55, 97–105. https://doi.org/10.1097/00005072-199601000-00010 (1996).
Caproni, S. & Colosimo, C. Diagnosis and differential diagnosis of Parkinson disease. Clin. Geriatr. Med. 36, 13–24. https://doi.org/10.1016/j.cger.2019.09.014 (2020).
Greene, P. Progressive supranuclear palsy, corticobasal degeneration, and multiple system atrophy. Continuum (Minneap Minn) 25, 919–935. https://doi.org/10.1212/CON.0000000000000751 (2019).
Ali, F. et al. Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy. Mov. Disord. 34, 1144–1153. https://doi.org/10.1002/mds.27619 (2019).
Hoglinger, G. U. et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov. Disord. 32, 853–864. https://doi.org/10.1002/mds.26987 (2017).
Litvan, I. et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop. Neurology 47, 1–9. https://doi.org/10.1212/wnl.47.1.1 (1996).
Armstrong, M. J. Progressive supranuclear palsy: An update. Curr. Neurol. Neurosci. Rep. 18, 12. https://doi.org/10.1007/s11910-018-0819-5 (2018).
Whitwell, J. L. et al. Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. Mov. Disord. 32, 955–971. https://doi.org/10.1002/mds.27038 (2017).
Tripathi, M. et al. Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography. Neuroradiology 55, 483–492. https://doi.org/10.1007/s00234-012-1132-7 (2013).
Pirker, W. et al. [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov. Disord. 15, 1158–1167. https://doi.org/10.1002/1531-8257(200011)15:6%3c1158::aid-mds1015%3e3.0.co;2-0 (2000).
Van Laere, K. et al. Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis. J. Nucl. Med. 47, 384–392 (2006).
Leuzy, A. et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol. Psychiatry 24, 1112–1134. https://doi.org/10.1038/s41380-018-0342-8 (2019).
Smith, R. et al. Increased basal ganglia binding of (18) F-AV-1451 in patients with progressive supranuclear palsy. Mov. Disord. 32, 108–114. https://doi.org/10.1002/mds.26813 (2017).
Whitwell, J. L. et al. [(18) F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. Mov. Disord. 32, 124–133. https://doi.org/10.1002/mds.26834 (2017).
Cho, H. et al. Subcortical (18) F-AV-1451 binding patterns in progressive supranuclear palsy. Mov. Disord. 32, 134–140. https://doi.org/10.1002/mds.26844 (2017).
Whitwell, J. L. et al. MRI outperforms [18F]AV-1451 PET as a longitudinal biomarker in progressive supranuclear palsy. Mov. Disord. 34, 105–113. https://doi.org/10.1002/mds.27546 (2019).
Smith, R. et al. Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy. Acta Neuropathol. 133, 149–151. https://doi.org/10.1007/s00401-016-1650-1 (2017).
Ng, K. P. et al. Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain. Alzheimer’s Res. Ther. 9, 25–25. https://doi.org/10.1186/s13195-017-0253-y (2017).
Ng, K. P. et al. Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [(18)F]THK5351 uptake in progressive supranuclear palsy. Neuroimage Clin. 24, 102091–102091. https://doi.org/10.1016/j.nicl.2019.102091 (2019).
Ishiki, A. et al. Neuroimaging-pathological correlations of [(18)F]THK5351 PET in progressive supranuclear palsy. Acta Neuropathol. Commun. 6, 53. https://doi.org/10.1186/s40478-018-0556-7 (2018).
Brendel, M. et al. [(18)F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy. Front. Aging Neurosci. 9, 440. https://doi.org/10.3389/fnagi.2017.00440 (2017).
Ishiki, A. et al. Tau imaging with [(18) F]THK-5351 in progressive supranuclear palsy. Eur. J. Neurol. 24, 130–136. https://doi.org/10.1111/ene.13164 (2017).
Hsu, J. L. et al. Improved predictive ability of the Montreal Cognitive Assessment for diagnosing dementia in a community-based study. Alzheimer’s Res. Ther. 7, 69. https://doi.org/10.1186/s13195-015-0156-8 (2015).
Hsiao, I. T. et al. Biodistribution and radiation dosimetry for the Tau Tracer (18)F-THK-5351 in healthy human subjects. J. Nucl. Med. 58, 1498–1503. https://doi.org/10.2967/jnumed.116.189126 (2017).
Lin, S. Y. et al. Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer’s disease. Alzheimer’s Res. Ther. 11, 111. https://doi.org/10.1186/s13195-019-0566-0 (2019).
Ashburner, J. & Friston, K. J. Unified segmentation. Neuroimage 26, 839–851. https://doi.org/10.1016/j.neuroimage.2005.02.018 (2005).
Jung Lung, H., Weng, Y. H., Wen, M. C., Hsiao, I. T. & Lin, K. J. Quantitative study of (18)F-(+)DTBZ image: Comparison of PET template-based and MRI based image analysis. Sci. Rep. 8, 16027. https://doi.org/10.1038/s41598-018-34388-6 (2018).
Gonzalez-Escamilla, G. et al. PETPVE12: An SPM toolbox for partial volume effects correction in brain PET—Application to amyloid imaging with AV45-PET. Neuroimage 147, 669–677. https://doi.org/10.1016/j.neuroimage.2016.12.077 (2017).
Ashburner, J. A fast diffeomorphic image registration algorithm. Neuroimage 38, 95–113. https://doi.org/10.1016/j.neuroimage.2007.07.007 (2007).
Frazier, J. A. et al. Structural brain magnetic resonance imaging of limbic and thalamic volumes in pediatric bipolar disorder. Am. J. Psychiatry 162, 1256–1265. https://doi.org/10.1176/appi.ajp.162.7.1256 (2005).
Massey, L. A. et al. The midbrain to pons ratio: A simple and specific MRI sign of progressive supranuclear palsy. Neurology 80, 1856–1861. https://doi.org/10.1212/WNL.0b013e318292a2d2 (2013).
Passamonti, L. et al. 18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy. Brain 140, 781–791. https://doi.org/10.1093/brain/aww340 (2017).
Lowe, V. J. et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol. Commun. 4, 58. https://doi.org/10.1186/s40478-016-0315-6 (2016).
Sander, K. et al. Characterization of tau positron emission tomography tracer [(18)F]AV-1451 binding to postmortem tissue in Alzheimer’s disease, primary tauopathies, and other dementias. Alzheimers Dement. 12, 1116–1124. https://doi.org/10.1016/j.jalz.2016.01.003 (2016).
Coakeley, S. et al. [(18)F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. Brain Struct. Funct. 223, 589–595. https://doi.org/10.1007/s00429-017-1507-y (2018).
Hsu, J. L. et al. The imaging features and clinical associations of a novel Tau PET Tracer-18F-APN1607 in Alzheimer disease. Clin. Nucl. Med. 45, 747–756. https://doi.org/10.1097/rlu.0000000000003164 (2020).
Weng, C. C. et al. Characterization of (18)F-PM-PBB3 ((18)F-APN-1607) uptake in the rTg4510 mouse model of tauopathy. Molecules (Basel, Switzerland). https://doi.org/10.3390/molecules25071750 (2020).
Quattrone, A. et al. Imaging counterpart of postural instability and vertical ocular dysfunction in patients with PSP: A multimodal MRI study. Parkinson. Relat. Disord. 63, 124–130. https://doi.org/10.1016/j.parkreldis.2019.02.022 (2019).
Josephs, K. A. et al. Modeling trajectories of regional volume loss in progressive supranuclear palsy. Mov. Disord. 28, 1117–1124. https://doi.org/10.1002/mds.25437 (2013).
Quattrone, A. et al. MR parkinsonism index predicts vertical supranuclear gaze palsy in patients with PSP-parkinsonism. Neurology 87, 1266–1273. https://doi.org/10.1212/WNL.0000000000003125 (2016).
Chan, L. L. et al. Transcallosal diffusion tensor abnormalities in predominant gait disorder parkinsonism. Parkinson. Relat. Disord. 20, 53–59. https://doi.org/10.1016/j.parkreldis.2013.09.017 (2014).
Zwergal, A. et al. Postural imbalance and falls in PSP correlate with functional pathology of the thalamus. Neurology 77, 101–109. https://doi.org/10.1212/WNL.0b013e318223c79d (2011).
Kurz, C. et al. An autopsy-confirmed case of progressive supranuclear palsy with predominant postural instability. Acta Neuropathol. Commun. 4, 120. https://doi.org/10.1186/s40478-016-0391-7 (2016).
Schonecker, S. et al. PET imaging of astrogliosis and tau facilitates diagnosis of Parkinsonian syndromes. Front. Aging Neurosci. 11, 249. https://doi.org/10.3389/fnagi.2019.00249 (2019).
Jacobacci, F. et al. Improving Spatial normalization of brain diffusion MRI to measure longitudinal changes of tissue microstructure in the cortex and white matter. J. Magn. Reson. Imaging https://doi.org/10.1002/jmri.27092 (2020).
Acknowledgements
The authors acknowledge the administrative support of the Chang Gung Memorial Hospital Clinical Trial Center—which is funded by the Taiwanese Ministry of Health and Welfare (grants MOHW104-TDU-B-212-113003, MOHW105-TDU-B-212-13302, and MOHW106-TDU-B-212-113005). This study was financially supported by grants from the Taiwanese Ministry of Health and Welfare (MOHW107-TDU-B-212-123005, MOHW108-TDU-B-212-133005), Ministry of Science and Technology (MOST 106-2314-B-182A-026-MY3, MOST 106-2314-B-182-017-MY3), and the Chang Gung Memorial Hospital Research Fund (CMRPG3F2181, CORPG3J0342, BMRPD69, CMRPG3D1293, CMRPG3J0371, CMRPD1H0391-3, BMRP488).
Author information
Authors and Affiliations
Contributions
J.L.H., K.J.L., and Y.H.W. designed the study. C.S.L. and Y.H.W. contributed to the study design and carried out the experimental work. J.L.H., I.T.H., S.H.C., and K.J.L. participated in data collection and analysis. J.L.H., K.J.L., and Y.H.W. revised the manuscript for important intellectual content. All listed authors have contributed significantly and met the criteria for authorship.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Hsu, JL., Chen, SH., Hsiao, IT. et al. 18F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty. Sci Rep 10, 19410 (2020). https://doi.org/10.1038/s41598-020-76339-0
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-020-76339-0
- Springer Nature Limited
This article is cited by
-
Tau PET imaging in progressive supranuclear palsy: a systematic review and meta-analysis
Journal of Neurology (2023)
-
An Update on the State of Tau Radiotracer Development: a Brief Review
Molecular Imaging and Biology (2021)